Effects of memantine on the excitation-inhibition balance in prefrontal cortex
Neurobiology of Disease, 2016 Memantine is one of the few drugs currently approved for treatment of Alzheimer's disease (AD). The clinical effects of memantine are thought to be associated with inhibition of NMDA receptors (NMDARs).
Nadezhda V. Povysheva, Jon W. Johnson
doaj +1 more source
Memantine ameliorates cognitive deficit in AD mice via enhancement of entorhinal–CA1 projection
BMC Neuroscience, 2021 Background Memantine, a low- to moderate-affinity uncompetitive N-methyl-D-aspartate receptor antagonist, has been shown to improve cognitive functions in animal models of Alzheimer’s disease (AD).
Peng Li +5 more
doaj +1 more source
Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. [PDF]
, 2016 BACKGROUND: Refractory migraine is a challenging condition with great impact on health related quality of life. Intravenous (IV) ketamine has been previously used to treat various refractory pain conditions.
Ashina, Sait +3 more
core +3 more sources
Memantine as an Augmentation Therapy for Anxiety Disorders
Case Reports in Psychiatry, 2012 Objective. Glutamate, an excitatory neurotransmitter in the central nervous system (CNS), may play a role in the development of anxiety. Memantine partially blocks N-methyl-D-aspartate (NMDA) receptors' glutamate channels located in the CNS.
Thomas L. Schwartz +2 more
doaj +1 more source
Memantine has no effect on KATP channels in pancreatic β cells
BMC Research Notes, 2018 Objective Memantine, a drug for Alzheimer’s disease, is considered to suppress excessive stimulation of N-methyl-d-aspartic acid receptors and to prevent neuronal death.
Ryota Imai +6 more
doaj +1 more source
Effectiveness of the Combination of Memantine Plus Vitamin D on Cognition in Patients With Alzheimer Disease: A Pre-Post Pilot Study [PDF]
, 2012 Objective: To determine whether treatment with memantine plus vitamin D is more effective than memantine or vitamin D alone in improving cognition among patients with Alzheimer disease (AD).
B. Brugg +4 more
core +5 more sources
Early intervention combined with targeted treatment promotes cognitive and behavioral improvements in young children with fragile x syndrome. [PDF]
, 2012 Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability due to an expansion in the full mutation range (>200 CGG repeats) of the promoter region of the FMR1 gene leading to gene silencing.
Borodyanskara, Mariya +3 more
core +3 more sources
Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. [PDF]
PLoS ONE, 2012 BackgroundAgitation in Alzheimer's disease (AD) is common and associated with poor patient life-quality and carer distress. The best evidence-based pharmacological treatments are antipsychotics which have limited benefits with increased morbidity and ...
Chris Fox +9 more
doaj +1 more source
In vivo study of pharmacokinetic parameters of a new combination drug based on citicoline and memantine [PDF]
Research Results in Pharmacology, 2021 Introduction: Cognitive impairment (dementia) is one of the most common pathologies with increasing numbers of patients. Most often they are the symptoms of Alzheimer’s disease and vascular brain diseases, for which such drugs as memantine and citicoline
Boris B. Sysuev, Damir K. Salakhetdinov
doaj +3 more sources
Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment Design and Cohort Baseline Characteristics of the German Dementia Competence Network [PDF]
, 2009 Background: The German Dementia Competence Network (DCN) has established procedures for standardized multicenter acquisition of clinical, biological and imaging data, for centralized data management, and for the evaluation of new treatments.
Frölich, Lutz +21 more
core +1 more source